ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 263 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $597,025 | -12.2% | 36,740 | -0.0% | 0.76% | +73.5% |
| Q1 2024 | $679,600 | -39.9% | 36,755 | +1.8% | 0.44% | -35.5% |
| Q4 2023 | $1,130,604 | +231.8% | 36,110 | +120.8% | 0.68% | +213.9% |
| Q3 2023 | $340,797 | -13.1% | 16,353 | -0.1% | 0.22% | -21.2% |
| Q2 2023 | $392,014 | +27.2% | 16,368 | -0.1% | 0.27% | -14.4% |
| Q1 2023 | $308,272 | +115791.7% | 16,380 | -2.1% | 0.32% | +69.3% |
| Q4 2022 | $266 | -99.9% | 16,739 | -0.0% | 0.19% | -18.2% |
| Q3 2022 | $274,000 | +19.7% | 16,743 | +2.8% | 0.23% | +32.8% |
| Q2 2022 | $229,000 | -42.0% | 16,281 | -0.1% | 0.17% | -23.3% |
| Q1 2022 | $395,000 | +1.5% | 16,290 | -2.3% | 0.23% | +25.4% |
| Q4 2021 | $389,000 | +40.4% | 16,665 | -0.0% | 0.18% | +79.2% |
| Q3 2021 | $277,000 | -35.0% | 16,668 | -4.6% | 0.10% | -28.9% |
| Q2 2021 | $426,000 | -5.5% | 17,479 | +0.0% | 0.14% | -49.3% |
| Q1 2021 | $451,000 | -52.3% | 17,472 | -23.8% | 0.28% | -45.8% |
| Q3 2020 | $945,000 | -14.6% | 22,916 | +0.3% | 0.52% | -21.1% |
| Q2 2020 | $1,107,000 | +14.7% | 22,847 | 0.0% | 0.66% | +56.7% |
| Q1 2020 | $965,000 | +2.7% | 22,847 | +4.0% | 0.42% | +25.5% |
| Q4 2019 | $940,000 | +19.9% | 21,963 | +0.8% | 0.33% | -23.1% |
| Q3 2019 | $784,000 | +65.8% | 21,796 | +23.2% | 0.43% | +132.8% |
| Q2 2019 | $473,000 | +91.5% | 17,697 | +92.3% | 0.19% | +104.4% |
| Q1 2019 | $247,000 | -7.1% | 9,203 | -28.2% | 0.09% | -79.8% |
| Q3 2018 | $266,000 | -3.6% | 12,825 | +4.5% | 0.45% | +309.1% |
| Q1 2018 | $276,000 | -25.4% | 12,273 | 0.0% | 0.11% | -39.2% |
| Q4 2017 | $370,000 | -15.3% | 12,273 | +5.7% | 0.18% | -59.6% |
| Q3 2017 | $437,000 | -47.6% | 11,607 | -59.9% | 0.45% | +4.7% |
| Q4 2016 | $834,000 | +124.2% | 28,913 | +147.2% | 0.43% | +1088.9% |
| Q3 2016 | $372,000 | – | 11,696 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 474,741 | $7,557,877 | 7.35% |
| Finepoint Capital LP | 1,176,830 | $18,735 | 6.06% |
| Baker Brothers Advisors | 41,923,486 | $667,421,897 | 4.01% |
| Palo Alto Investors LP | 2,376,369 | $37,831,794 | 3.23% |
| EcoR1 Capital, LLC | 5,991,479 | $95,384,346 | 2.90% |
| Birchview Capital, LP | 249,400 | $3,970 | 2.80% |
| Ikarian Capital, LLC | 325,000 | $5,174,001 | 1.25% |
| Bain Capital Life Sciences Investors, LLC | 701,402 | $11,166 | 1.25% |
| RTW INVESTMENTS, LP | 3,670,938 | $58,441,333 | 1.19% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,048,750 | $16,696,100 | 1.03% |